Cargando…
In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer
BACKGROUND: Abnormal glucose and lipid metabolism plays a critical role in gastric carcinogenesis and development. Hence, we presented a systematic analysis of glucose and lipid metabolism-related genes to explore their function and prognostic value in gastric cancer (GC). METHODS: The consensus clu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372230/ https://www.ncbi.nlm.nih.gov/pubmed/35966316 http://dx.doi.org/10.21037/tcr-22-168 |
_version_ | 1784767333966807040 |
---|---|
author | Yang, Yuan Chen, Zhaofeng Zhou, Lingshan Wu, Guozhi Ma, Xiaomei Zheng, Ya Liu, Min Wang, Yuping Ji, Rui Guo, Qinghong Zhou, Yongning |
author_facet | Yang, Yuan Chen, Zhaofeng Zhou, Lingshan Wu, Guozhi Ma, Xiaomei Zheng, Ya Liu, Min Wang, Yuping Ji, Rui Guo, Qinghong Zhou, Yongning |
author_sort | Yang, Yuan |
collection | PubMed |
description | BACKGROUND: Abnormal glucose and lipid metabolism plays a critical role in gastric carcinogenesis and development. Hence, we presented a systematic analysis of glucose and lipid metabolism-related genes to explore their function and prognostic value in gastric cancer (GC). METHODS: The consensus clustering algorithm was used to identify the molecular subtypes based on glucose and lipid metabolism-related genes. Subsequently, cox regression analysis and lasso regression analysis were utilized to establish a risk prediction model. A clinical nomogram was constructed to assist prognosis assessment. In addition, ESTIMATE and single-sample gene set enrichment analysis (ssGSEA) algorithms were performed to evaluate the immune infiltration of the metabolic model, and GSEA was used for enrichment analysis of the metabolic signature. Finally, we explored the association between the risk model and anti-cancer therapy for the purpose of clinical application for GC treatment. RESULTS: GC samples were divided into 2 subtypes based on glucose and lipid metabolism-related genes, patients in cluster 2 had a better overall survival (OS) than those in cluster 1. Fifty-two genes were identified by univariable regression analysis. Finally, a 13-gene metabolic signature (CACNA1H, CHST1, IGFBP3, NASP, STC1, VCAN, NUP205, NUP43, PGM2L1, CAV1, ELOVL4, PRKAA2, TNFAIP8L3) was successfully constructed that demonstrated good performance in different datasets, as well as an independent hazardous factor for prognosis. In addition, the nomogram constructed with the clinical variables showed higher predictive efficacy for predicting the 1-, 3-, and 5-year OS. The 13-gene metabolic signature was significantly associated with immune scores and immune cell infiltration in high-risk group. Moreover, GSEA analysis revealed that cancer- and immune-related pathways were enriched in the high-risk group. Finally, our results indicated that there might exist an immunosuppressive status in the high-risk groups. CONCLUSIONS: This study demonstrated that glucose and lipid metabolism-related genes were significantly associated with prognosis. Meanwhile, it will provide novel insights into exploring the immunoregulation roles of these genes. |
format | Online Article Text |
id | pubmed-9372230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-93722302022-08-13 In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer Yang, Yuan Chen, Zhaofeng Zhou, Lingshan Wu, Guozhi Ma, Xiaomei Zheng, Ya Liu, Min Wang, Yuping Ji, Rui Guo, Qinghong Zhou, Yongning Transl Cancer Res Original Article BACKGROUND: Abnormal glucose and lipid metabolism plays a critical role in gastric carcinogenesis and development. Hence, we presented a systematic analysis of glucose and lipid metabolism-related genes to explore their function and prognostic value in gastric cancer (GC). METHODS: The consensus clustering algorithm was used to identify the molecular subtypes based on glucose and lipid metabolism-related genes. Subsequently, cox regression analysis and lasso regression analysis were utilized to establish a risk prediction model. A clinical nomogram was constructed to assist prognosis assessment. In addition, ESTIMATE and single-sample gene set enrichment analysis (ssGSEA) algorithms were performed to evaluate the immune infiltration of the metabolic model, and GSEA was used for enrichment analysis of the metabolic signature. Finally, we explored the association between the risk model and anti-cancer therapy for the purpose of clinical application for GC treatment. RESULTS: GC samples were divided into 2 subtypes based on glucose and lipid metabolism-related genes, patients in cluster 2 had a better overall survival (OS) than those in cluster 1. Fifty-two genes were identified by univariable regression analysis. Finally, a 13-gene metabolic signature (CACNA1H, CHST1, IGFBP3, NASP, STC1, VCAN, NUP205, NUP43, PGM2L1, CAV1, ELOVL4, PRKAA2, TNFAIP8L3) was successfully constructed that demonstrated good performance in different datasets, as well as an independent hazardous factor for prognosis. In addition, the nomogram constructed with the clinical variables showed higher predictive efficacy for predicting the 1-, 3-, and 5-year OS. The 13-gene metabolic signature was significantly associated with immune scores and immune cell infiltration in high-risk group. Moreover, GSEA analysis revealed that cancer- and immune-related pathways were enriched in the high-risk group. Finally, our results indicated that there might exist an immunosuppressive status in the high-risk groups. CONCLUSIONS: This study demonstrated that glucose and lipid metabolism-related genes were significantly associated with prognosis. Meanwhile, it will provide novel insights into exploring the immunoregulation roles of these genes. AME Publishing Company 2022-07 /pmc/articles/PMC9372230/ /pubmed/35966316 http://dx.doi.org/10.21037/tcr-22-168 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Yang, Yuan Chen, Zhaofeng Zhou, Lingshan Wu, Guozhi Ma, Xiaomei Zheng, Ya Liu, Min Wang, Yuping Ji, Rui Guo, Qinghong Zhou, Yongning In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer |
title | In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer |
title_full | In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer |
title_fullStr | In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer |
title_full_unstemmed | In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer |
title_short | In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer |
title_sort | in silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372230/ https://www.ncbi.nlm.nih.gov/pubmed/35966316 http://dx.doi.org/10.21037/tcr-22-168 |
work_keys_str_mv | AT yangyuan insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT chenzhaofeng insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT zhoulingshan insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT wuguozhi insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT maxiaomei insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT zhengya insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT liumin insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT wangyuping insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT jirui insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT guoqinghong insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer AT zhouyongning insilicodevelopmentandvalidationofanovelglucoseandlipidmetabolismrelatedgenesignatureingastriccancer |